DOCSLIB.ORG

Diverse Immunotherapies Can Effectively Treat Syngeneic Brainstem Tumors in the Absence of Overt Toxicity Matthew R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diverse Immunotherapies Can Effectively Treat Syngeneic Brainstem Tumors in the Absence of Overt Toxicity Matthew R Schuelke et al. Journal for ImmunoTherapy of Cancer (2019) 7:188 https://doi.org/10.1186/s40425-019-0673-2 RESEARCHARTICLE Open Access Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity Matthew R. Schuelke1,2, Phonphimon Wongthida3, Jill Thompson3, Timothy Kottke3, Christopher B. Driscoll4, Amanda L. Huff4, Kevin G. Shim1,2, Matt Coffey5, Jose Pulido6, Laura Evgin3 and Richard G. Vile1,3,7* Abstract Background: Immunotherapy has shown remarkable clinical promise in the treatment of various types of cancers. However, clinical benefits derive from a highly inflammatory mechanism of action. This presents unique challenges for use in pediatric brainstem tumors including diffuse intrinsic pontine glioma (DIPG), since treatment-related inflammation could cause catastrophic toxicity. Therefore, the goal of this study was to investigate whether inflammatory, immune- based therapies are likely to be too dangerous to pursue for the treatment of pediatric brainstem tumors. Methods: To complement previous immunotherapy studies using patient-derived xenografts in immunodeficient mice, we developed fully immunocompetent models of immunotherapy using transplantable, syngeneic tumors. These four models – HSVtk/GCV suicide gene immunotherapy, oncolytic viroimmunotherapy, adoptive T cell transfer, and CAR T cell therapy – have been optimized to treat tumors outside of the CNS and induce a broad spectrum of inflammatory profiles, maximizing the chances of observing brainstem toxicity. Results: All four models achieved anti-tumor efficacy in the absence of toxicity, with the exception of recombinant vaccinia virus expressing GMCSF, which demonstrated inflammatory toxicity. Histology, imaging, and flow cytometry confirmed the presence of brainstem inflammation in all models. Where used, the addition of immune checkpoint blockade did not introduce toxicity. Conclusions: It remains imperative to regard the brainstem with caution for immunotherapeutic intervention. Nonetheless, we show that further careful development of immunotherapies for pediatric brainstem tumors is warranted to harness the potential potency of anti-tumor immune responses, despite their possible toxicity within this anatomically sensitive location. Keywords: Immunotherapy, Brainstem, Toxicity, DIPG Background unfortunately, decades of clinical research have not in- Brain tumors are the leading cause of pediatric cancer creased median overall survival beyond 9–11 months [2]. death [1]. Ten to 15 % of these tumors occur in the Cancer immunotherapy is among the most promising brainstem, most of which are a uniformly fatal disease areas of biomedical research, with recent FDA approval classified as an H3K27M-mutant diffuse midline glioma, of the first chimeric antigen receptor (CAR) T cell [4] or historically, diffuse intrinsic pontine glioma (DIPG) and oncolytic virus [5] therapies. In addition to strong [2, 3]. Radiation extends survival by several months and anti-tumor activity, these treatments have the potential dexamethasone is used for symptomatic control, but to provide long-term cancer immunosurveillance through the generation of immunologic memory [6, 7]. Furthermore, while traditional chemotherapy and radi- * Correspondence: [email protected] ation have long-term, developmental effects on pediatric 1Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA 3Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA patients [8], clinical studies in adults suggest that im- Full list of author information is available at the end of the article munotherapies may have favorable long-term safety © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Schuelke et al. Journal for ImmunoTherapy of Cancer (2019) 7:188 Page 2 of 13 profiles [9, 10], though ongoing studies are validating pcDNA3.1OVA and maintained in 10% DMEM with 5 mg/ this in children. mL G418 selection media. The B16-EGFRvIII cell line was However, brainstem gliomas like DIPG provide unique generated by retroviral transduction with pBABE PURO challenges for immunotherapy. Physiologically, the brain- encoding the murine EGFRvIII modified by the deletion of stem controls vital functions [11], requiring that therapies 500 aa from the intracellular domain of the protein using a avoid damage to healthy tissue. Infectious or autoimmune construct given as a kind gift from Dr. Luis Sanchez-Perez inflammation of the brainstem carries high morbidity and and Dr. John Sampson (Duke University, Durham, NC) mortality [12], raising concerns for cancer immunother- [18]. A clonally derived cell line was subsequently main- apies in this location. Additionally, DIPGs contain few tained in 1.25 μg/mL of puromycin. adaptive immune cells, suggesting a lack of functional Cell lines were authenticated by morphology, growth immunosurveillance and a need for induction of de novo characteristics, PCR for melanoma specific gene expres- immune responses [13, 14]. sion (gp100, TYRP-1 and TYRP-2) and biologic behavior, Thesedataraisethequestionofwhetherpotentiallycura- tested mycoplasma-free, and frozen. EGFRvIII-positive tive immunotherapy for brainstem tumors may generate cells were verified by flow cytometry staining with an anti- unacceptable toxicity. Preclinically, cancer vaccines [15] EGFRvIII primary antibody (L8A4). Cells were cultured and CAR T cells [16] have been studied in DIPG xenograft less than 3 months after thawing. Cells were tested for models, establishing evidence of anti-tumor efficacy. How- mycoplasma using the MycoAlert Mycoplasma Detection ever, while these human xenograft models allow for proof- Kit (Lonza Rockland, Inc. ME, USA). of-concept efficacy, exploration of immune-mediated tox- For recombinant vaccinia virus (VV) production, CV-1 icity and associated inflammation is best recapitulated in cells were infected by vaccinia virus (WR strain) and trans- an immunocompetent animal model. To this end, we used fected with the pSC65 plasmid transfer vector (a generous previously-validated syngeneic gliomas and melanomas to gift from Dr. Bernard Moss, NIAID) containing murine establish brainstem tumor models to assess a diverse range granulocyte monocyte colony stimulating factor (GM-CSF) of immunotherapies. Our goal was not to compare relative cDNA [19]. Recombinant viruses were isolated and then efficacies of each therapy, but rather to ascertain the poten- bulked up in Hela cells (ATCC, Manassass, VA), followed tial for immune-mediated toxicity in the brainstem. From by sucrose cushion purification. Purified virus was titered these studies, we demonstrate that although the possibility on Hela cells and stored at -80C. Clinical-grade reovirus of therapy-related inflammatory toxicity exists, a diverse was acquired from Oncolytics Biotech (Calgary, Canada). range of immunotherapies can extend survival of mice GL261 cells were infected with reovirus or VV- bearing syngeneic brainstem tumors without generating GMCSF at an MOI of 10 followed by exposure to Cell overt neurologic toxicity. These results suggest greater con- Titer Blue (Promega) for survival assessment or harvest- sideration of clinical immunotherapy trials for pediatric ing for replication assessment using a plaque assay on brainstem tumors. Hela cells (vaccinia) or L929 cells (reovirus). All vesicular stomatitis viruses (VSV) were generated Materials and methods as previously described [20]. Briefly, VSV (Indiana sero- Cell lines and viruses type) expressing human gp100 or chicken ovalbumin GL261 and GL261-QUAD cells were obtained from Dr. was generated by cloning the respective antigen into the Aaron Johnson (Mayo Clinic). GL261-QUAD cells were pVSV-XN2 plasmid by inserting between the VSV G and originally created by John Ohlfest, et al [17], and stably L proteins. VSV was titered by plaque assay on BHK express the model tumor antigens chicken OVA257–264, cells and stored at -80C. chicken OVA323–339,humangp10025–33,andthemouseal- loantigen I-Ea – .BothGL261tumorlinesweregrownin 52 68 Mice DMEM (HyClone, Logan, UT, USA) + 10% FBS (Life Tech- Female C57BL/6 mice at 6–8 weeks of age (Jackson nologies, Carlsbad, CA). B16.F1 parental murine melanoma Labs) were used for all in vivo experiments. OT-I [21] cells were obtained from the ATCC (Manassas, VA). B16tk and pmel [22] mice were bred at the Mayo Clinic, and cells were derived from a B16.F1 clone stably infected with harvested between 8 and 14 weeks of age for adoptive a lentivirus expressing the Herpes Simplex Virus thymidine transfer experiments. kinase (HSV-1 TK) gene. Following stable selection in 1.25 μg/mL puromycin, these cells were shown to be sensi- tive to Ganciclovir (APP Pharmaceuticals, Barceloneta, PR) Transgenic T cell preparation at 5 μg/ml. B16tk cells were grown in DMEM (HyClone, Pmel or OT-I T cells were harvested from transgenic Logan, UT, USA) + 10% FBS (Life Technologies, Carlsbad, pmel or OT-I mouse spleens, respectively, and under- CA) + 1.25 μg/mL puromycin (Sigma,
Load more

Recommended publications
  • New Perspectives for Gene Therapy in Endocrinology
    European Journal of Endocrinology (2000) 143 447±466 ISSN 0804-4643 INVITED REVIEW New perspectives for gene therapy in endocrinology Luisa Barzon, Roberta Bonaguro1, Giorgio PaluÁ 1 and Marco Boscaro Department of Medical and Surgical Sciences and 1Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Padova, Italy (Correspondence should be addressed to M Boscaro, Department of Medical and Surgical Sciences, University of Padova, Via Ospedale, 105, 35128 Padova, Italy; Email: [email protected], or to G PaluÁ, Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Via A Gabelli, 63, 35121 Padova, Italy; Email: [email protected]) Abstract Gene therapy for endocrine diseases represents an exciting new type of molecular intervention that may be a curative one. Endocrine disorders that might be treated by gene therapy include monogenic diseases, such as GH de®ciency and hypothalamic diabetes insipidus, and multifactorial diseases, such as diabetes mellitus, obesity and cancer. Premises seem promising for endocrine tumours, but many combined approaches of cell and gene therapy are foreseeable also for other endocrine disorders. This review outlines the principles of gene therapy, describes the endocrine disorders that might take advantage of gene transfer approaches, as well as the gene therapy interventions that have already been attempted, their major limitations and the problems that remain to be solved. European Journal of Endocrinology 143 447±466 Introduction in 1989 (data from Journal of Gene Medicine, www. wiley.co.uk/genmed, updated to 1 September 1999) (1). In the last three decades scienti®c progress in biomedi- Even though the disorders targeted by gene therapy cal research has revealed the molecular mechanisms approaches span the entire spectrum of human and genetic bases of many human diseases.
    [Show full text]
  • Recombinant Dna Advisory Committee
    RECOMBINANT DNA ADVISORY COMMITTEE Minutes of Meeting March 7 and 8, 2012 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health Minutes of the Recombinant DNA Advisory Committee, 3/7–8/12 Contents I. Call to Order and Opening Remarks ................................................................................................... 2 II. Review and Discussion of Human Gene Transfer Protocol #1201-1144 titled: AAV8-Mediated Low Density Lipoprotein Receptor Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia .......................................................................................................................... 2 A. Protocol Summary ........................................................................................................................ 2 B. Written Reviews by RAC Members .............................................................................................. 3 C. RAC Discussion ............................................................................................................................ 4 D. Investigator Response .................................................................................................................. 4 1. Written Responses to RAC Reviews ..................................................................................... 4 2. Responses to RAC Discussion Questions ............................................................................. 6 E. Public Comment ...........................................................................................................................
    [Show full text]
  • Embryonic Stem Cells Modulate the Cancer-Permissive
    Theranostics 2019, Vol. 9, Issue 16 4764 Ivyspring International Publisher Theranostics 2019; 9(16): 4764-4778. doi: 10.7150/thno.33139 Research Paper Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma Jiahui Liu1*, Zheqian Huang1*, Liu Yang1, Xiaoran Wang1, Shoubi Wang1, Chaoyang Li1, Ying Liu1, Yaqi Cheng1, Bowen Wang1, Xuan Sang1, Xiongjun He1, Chenjie Wang1, Tengfei Liu1, ChengXiu Liu2, Lin Jin1, Chang Liu1, Xiaoran Zhang3, Linghua Wang4, Zhichong Wang1 1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, P. R. China. 2. Department of Ophthalmology, Affiliated Hospital of Qingdao University Medical College, Qingdao 266000, P. R. China 3. Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou 510275, P. R. China 4. Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. *These authors contributed equally to this work. Corresponding author: [email protected] © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.01.14; Accepted: 2019.05.14; Published: 2019.07.09 Abstract The currently used anti-cancer therapies work by killing cancer cells but result in adverse effects and resistance to treatment, which accelerates aging and causes damage to normal somatic cells. On one hand, chicken and zebrafish embryos can reprogram cancer cells towards a non-tumorigenic phenotype; however, they cannot be used in the clinical practice.
    [Show full text]
  • Suicide Genes and Bystander Killing: Local and Distant Effects
    Gene Therapy (1997) 4, 273–274 1997 Stockton Press All rights reserved 0969-7128/97 $12.00 Editorial Suicide genes and bystander killing: local suggested to exert a bystander effect in a clinical trial in 9 and distant effects patients with lung cancer. The same authors have pre- viously shown both in vitro and in vivo experimental ani- The mechanism underlying suicide gene therapy is not mal data indicative of a bystander effect. The underlying fully resolved but seems to be complex. Results from two mechanism is not known but may be via soluble factors recent studies1,2 now demonstrate that the level of com- inducing apoptosis. During the initial phase of the orig- plexity may have further increased. inal tumor development the preneoplastic cells are pre- Suicide gene therapy is one of several approaches to sumably resistant to the apoptotic effect, as the tumor, in treat cancer.3,4 A suicide gene encodes a protein that is fact, does develop. We would like to suggest that the toxic to the cell. Some suicide genes encode products that fully neoplastic cells may have acquired sensitivity to are directly toxic to the cell, such as diphtheria toxin or p53-induced apoptosis while undergoing additional gen- Pseudomonas exotoxin, both of which inhibit protein syn- etic changes. thesis. Other suicide genes give rise to enzymes that The suicide gene most commonly employed, both in selectively convert nontoxic prodrugs to highly toxic an experimental and a clinical setting,6,7 is the thymidine metabolites. These genes have also been used in trans- kinase gene of the herpes simplex virus (HSVtk).
    [Show full text]
  • Suicide Gene Therapy Against Cancer Taufiek K
    ndrom Sy es tic & e G n e e n G e f T o Rajab et al., J Genet Syndr Gene Ther 2013, 4:9 Journal of Genetic Syndromes h l e a r n a r p DOI: 10.4172/2157-7412.1000187 u y o J & Gene Therapy ISSN: 2157-7412 Review Article Open Access Suicide Gene Therapy against Cancer Taufiek K. Rajab2, Peter J. Nelson3, Emily Z Keung1,2 and Claudius Conrad1* 1Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA 2Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA 3Medizinische Klinik und Poliklinik IV, AG Biochemistry, University of Munich, Munich, Germany Abstract A major limitation of conventional chemotherapies used in cancer treatments today are low therapeutic indices and side effects that result from drug effects on normal tissues (off target). One of the most innovative approaches to developing antineoplastic agents with increased tumor selectivity is the use of suicide gene therapy. Suicide gene therapy involves delivering a gene product in proximity to the targeted cancer tissue through various targeted delivery methods followed by tissue/tumor-specific expression of the gene product which then converts a systemically available pro-drug into an active drug within the tumor locale. Here we summarize the concept of gene therapy for cancer and introduce the most frequently used suicide gene therapy systems. In addition we discuss viral, molecular and cellular vectors and their advantages and disadvantages. Finally, we describe the clinical applications, limitations and potential side effects of suicide gene therapy to date.
    [Show full text]
  • Recombinant Dna Advisory Committee
    RECOMBINANT DNA ADVISORY COMMITTEE Minutes of Meeting March 16, 2005 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health Minutes of the Recombinant DNA Advisory Committee – 3/16/05 CONTENTS I. Call to Order and Opening Remarks ................................................................................................... 2 II. Minutes of the December 16, 2004, RAC Meeting ............................................................................. 3 A. Committee Motion 1...................................................................................................................... 3 III. Update on Human Gene Transfer Protocol #9906-322: A Phase I Study of NGF Ex Vivo Gene Therapy for Alzheimer’s Disease (AD) ................................................................................................ 3 IV. Update on Human Gene Transfer Protocol #0401-623: A Phase I/II, Dose-Escalating, Randomized and Controlled Study to Assess the Safety, Tolerability, and Efficacy of CERE-110 (AAV-Based, Vector-Mediated Delivery of Beta-NGF) in Subjects with Mild to Moderate AD............ 3 V. Discussion of Human Gene Transfer Protocol #0501-689: A Phase I, Open-Label Study of CERE-120 AAV Serotype 2-Neurturin (NTN) to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects with Idiopathic Parkinson’s Disease (PD)........................................................... 4 A. Protocol Summary.......................................................................................................................
    [Show full text]
  • Engineering Stem Cells for Biomedical Applications
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Adv Healthc Manuscript Author Mater. Author Manuscript Author manuscript; available in PMC 2018 February 13. Published in final edited form as: Adv Healthc Mater. 2016 January 07; 5(1): 10–55. doi:10.1002/adhm.201400842. Engineering Stem Cells for Biomedical Applications Perry T. Yin, Department of Biomedical Engineering Rutgers, The State University of New Jersey, 599 Taylor Road, Piscataway, NJ 08854, USA Edward Han, and Institute of Biomaterials and Biomedical Engineering University of Toronto, 164 College Street, Toronto, ON, M5S 3G9, Canada Prof. Ki-Bum Lee Department of Biomedical Engineering Rutgers, The State University of New Jersey, 599 Taylor Road, Piscataway, NJ 08854, USA. Department of Chemistry and Chemical Biology Rutgers, The State University of New Jersey 610 Taylor Road, Piscataway, NJ 08854, USA Abstract Stem cells are characterized by a number of useful properties, including their ability to migrate, differentiate, and secrete a variety of therapeutic molecules such as immunomodulatory factors. As such, numerous pre-clinical and clinical studies have utilized stem cell-based therapies and demonstrated their tremendous potential for the treatment of various human diseases and disorders. Recently, efforts have focused on engineering stem cells in order to further enhance their innate abilities as well as to confer them with new functionalities, which can then be used in various biomedical applications. These engineered stem cells can take on a number of forms. For instance, engineered stem cells encompass the genetic modification of stem cells as well as the use of stem cells for gene delivery, nanoparticle loading and delivery, and even small molecule drug delivery.
    [Show full text]
  • Methods and Protocols M ETHODS in M OLECULAR B IOLOGY
    Methods in Molecular Biology 1895 Nejat Düzgüneş Editor Suicide Gene Therapy Methods and Protocols M ETHODS IN M OLECULAR B IOLOGY Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Suicide Gene Therapy Methods and Protocols Edited by Nejat Düzgüneş Department of Biomedical Sciences, Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, CA, USA Editor Nejat Du¨zgu¨nes¸ Department of Biomedical Sciences Arthur A. Dugoni School of Dentistry University of the Pacific San Francisco, CA, USA ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-8921-8 ISBN 978-1-4939-8922-5 (eBook) https://doi.org/10.1007/978-1-4939-8922-5 Library of Congress Control Number: 2018961739 © Springer Science+Business Media, LLC, part of Springer Nature 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication.
    [Show full text]
  • Mode of Cell Death Associated with Adenovirus-Mediated Suicide Gene Therapy in HNSCC Tumor Model
    ANTICANCER RESEARCH 31: 3851-3858 (2011) Mode of Cell Death Associated with Adenovirus-mediated Suicide Gene Therapy in HNSCC Tumor Model DEEPIKA SRIVASTAVA1, GANESH JOSHI1, KUMARAVEL SOMASUNDARAM2 and RITA MULHERKAR1 1Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India; 2Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India Abstract. Background: Adenoviral mediated suicide gene via chain termination after incorporation of GCV- therapy has been shown to have a tumoricidal effect against triphosphate into replicating DNA as well as inhibition of a variety of tumor models. Although the efficacy of this DNA polymerase alpha (1). Another promising aspect of this treatment regimen has been verified, the molecular mechanism strategy is the “bystander effect” where the cytotoxic of Herpes simplex virus thymidine kinase gene (HSVtk)- and molecules (GCV-triphosphate) are taken up by the ganciclovir (GCV)-induced cell death is still not well neighboring untransduced cells via gap junctions thereby established. Materials and Methods: The mode of cell death enhancing tumour cell kill (2-6). by adenoviral (Adv)-HSVtk/GCV was examined in the head The cytocidal efficacy of the HSVtk/GCV system in the and neck squamous cell carcinoma cell line, NT8e. Results: treatment of various tumors has been demonstrated both in The cell death was independent of apoptotic gene expression. vitro and in vivo (7-9). Apoptosis has been suggested as the Moreover apoptosis was not evident from cell cycle kinetic cytocidal mechanism of Adv-HSVtk/GCV transduced cells analysis. Adv-HSVtk/GCV treated cells showed time dependent (10-13). A study on colorectal cancer (14) showed a accumulation of cells in the S-phase of the cell cycle although combination of apoptosis in the G1 cell cycle phase and late there was no increase in the “apoptotic peak” or sub-G1 apoptotic or necrotic sub-G1 DNA fragmentation, depending population.
    [Show full text]
  • Suicide Gene Therapy for Cancer
    ndrom Sy es tic & e G n e e n G e f T o Zarogoulidis et al., J Genet Syndr Gene Ther 2013, 4:4 Journal of Genetic Syndromes h l e a r n a r p DOI: 10.4172/2157-7412.1000139 u y o J & Gene Therapy ISSN: 2157-7412 Review Article Open Access Suicide Gene Therapy for Cancer – Current Strategies Paul Zarogoulidis1,2, Kaid Darwiche2, Antonios Sakkas3, Lonny Yarmus4, Haidong Huang5, Qiang Li5, Lutz Freitag2, Konstantinos Zarogoulidis1, Marek Malecki6,7* 1Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, EU; 2Department of Interventional Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital, University Duisburg-Essen, Essen, Germany, EU; 3Pathology Department, “G. Papanikolaou” General Hospital, Thessaloniki, Greece, EU; 4Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, USA; 5Department of Respiratory Diseases, Changhai Hospital/First Affiliated Hospital of the Second Military Medical University, Shanghai, China; 6Phoenix Biomolecular Engineering Foundation, San Francisco, CA, USA; 7University of Wisconsin, Madison, WI, USA Abstract Current cancer treatments may create profound iatrogenic outcomes. The adverse effects of these treatments still remain, as the serious problems that practicing physicians have to cope with in clinical practice. Although, non- specific cytotoxic agents constitute an effective treatment modality against cancer cells, they also tend to kill normal, quickly dividing cells. On the other hand, therapies targeting the genome of the tumors are both under investigation, and some others are already streamlined to clinical practice. Several approaches have been investigated in order to find a treatment targeting the cancer cells, while not affecting the normal cells.
    [Show full text]
  • View Final Program
    BALTIMORE MARRIOTT WATERFRONT HOTEL OCTOBER 15, 2016 PRE-MEETING SYMPOSIUM The Neuroscience of Consciousness and Coma ANA ANNUAL MEETING FINAL PROGRAM www.2016.myana.org www.myana.org 141st ANNUAL MEETING OF THE AMERICAN ANA2016 NEUROLOGICAL ASSOCIATION 2016 THE 141ST ANA TABLE OF CONTENTS ANNUAL MEETING Enjoy outstanding scientific symposia LETTER FROM THE CHAIR .......................................3 covering the latest research in the fields of neurology and neuroscience and take the opportunity to network with leaders SCHEDULE AT A GLANCE .........................................4 in the world of academic neurology at the 141st ANA Annual Meeting in Baltimore, Maryland, October 16-18, 2016. MEETING HIGHLIGHTS ............................................8 IMPORTANT DATES ANNUAL MEETING APP ...........................................8 Early Registration Deadline: August 29, 2016 MEETING REGISTRATION ........................................8 Hotel Reservation Deadline: October 1, 2016 PROGRAM BY DAY: Onsite Registration Opens: October 15, 2016 SATURDAY, OCTOBER 15 .....................................10 Pre-conference Symposium: October 15, 2016 SUNDAY, OCTOBER 16 .........................................10 NINDS Career Development MONDAY, OCTOBER 17 ........................................17 Meeting (invitation only): October 14 - 15, 2016 TUESDAY, OCTOBER 18 .......................................24 Annual Meeting Dates: October 16 - 18, 2016 SPEAKER ABSTRACTS .............................................27 2016 AWARD INFORMATION
    [Show full text]
  • In Vivo Cancer Gene Therapy by Adenovirus-Mediated Transfer of a Bifunctional Yeast Cytosine Deaminase/Uracil Phosphoribosyltransferase Fusion Gene
    [CANCER RESEARCH 60, 3813–3822, July 15, 2000] In Vivo Cancer Gene Therapy by Adenovirus-mediated Transfer of a Bifunctional Yeast Cytosine Deaminase/Uracil Phosphoribosyltransferase Fusion Gene Philippe Erbs,1 Etienne Regulier, Jacqueline Kintz, Pierre Leroy, Yves Poitevin, Franc¸oise Exinger, Richard Jund, and Majid Mehtali Transgene S.A., 67082 Strasbourg Cedex, France [P. E., E. R., J. K., P. L., Y. P.]; Laboratoire de Ge´ne´tique, Centre National de la Recherche Scientifique, UPR 9003, Institut de Recherche contre les Cancers de l’Appareil Digestif, Hoˆpital Civil, 67091 Strasbourg Cedex, France [F. E., R. J.]; and IntroGene BV, 2301 CA Leiden, the Netherlands [M. M.] ABSTRACT analogues, into their monophosphate forms, which are then further phosphorylated by cellular kinases into their di- and triphosphate Direct transfer of prodrug activation systems into tumors was demon- derivatives. Intracellular accumulation of such triphosphate metabo- strated to be an attractive method for the selective in vivo elimination of lites and their subsequent incorporation into nascent DNA strands tumor cells. However, most current suicide gene therapy strategies are still handicapped by a poor efficiency of in vivo gene transfer and a limited inhibit mammalian DNA polymerases and ultimately lead to cell bystander cell killing effect. In this study, we describe a novel and highly death (7). Interestingly, neighboring tumor cells that do not express potent suicide gene derived from the Saccharomyces cerevisiae cytosine the HSV-TK gene were also shown
    [Show full text]